Literature DB >> 10799609

Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells.

L Liu1, W F Anderson, R W Beart, E M Gordon, F L Hall.   

Abstract

Adhesion receptors expressed on the surfaces of tumor-activated endothelial cells provide an advantageous locus for targeting gene therapy vectors to angiogenic tissues and/or tumor vasculature. In this study, we engineered a series of Asn-Gly-Arg (NGR)-containing congeners of the presumptive cell binding motif contained within the ninth type III repeat of fibronectin and displayed these tumor vasculature targeting motifs (TVTMs) within the context of Moloney murine leukemia envelope "escort" proteins. Comparative studies of envelope incorporation into viral particles and evaluation of the cell binding properties of the targeted vectors revealed critical structural features, thus identifying a subset of optimal TVTMs. Utilizing a modified ELISA to evaluate viral binding to target cells, we observed a significant down-regulation of TVTM-virion binding to human endothelial cells following sustained (48-h) exposure to VEGF. Normalized for equivalent titers (10(6) CFU/ml), as assayed on NIH 3T3 cells, vectors displaying TVTM escort proteins significantly enhanced the transduction efficiency from 12.2 to 37.4% in human KSY-1 endothelial cell cultures (P < 0.001) and from 0.4 to 4.1% in human umbilical vein endothelial cell (HUVEC) cultures (P < 0.001). In summary, these studies utilized an engineering approach to identify a subset of TVTMs that are stably incorporated as envelope "escort" proteins into retroviral vectors and that, by functioning to improve the binding efficiency and transduction of both HUVEC and KSY1 endothelial cells, may have therapeutic potential for targeting gene delivery to the tumor-associated vasculature.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799609      PMCID: PMC110887          DOI: 10.1128/jvi.74.11.5320-5328.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

2.  Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor.

Authors:  J A Nagy; I A Eckelhoefer; E M Masse; A M Dvorak; H F Dvorak
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

3.  Complete primary structure of bovine plasma fibronectin.

Authors:  K Skorstengaard; M S Jensen; P Sahl; T E Petersen; S Magnusson
Journal:  Eur J Biochem       Date:  1986-12-01

4.  Site-directed mutagenesis of the cell-binding domain of human fibronectin: separable, synergistic sites mediate adhesive function.

Authors:  M Obara; M S Kang; K M Yamada
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

Review 5.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.

Authors:  H F Dvorak; J A Nagy; A M Dvorak
Journal:  Cancer Cells       Date:  1991-03

6.  Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein.

Authors:  F L Hall; E M Gordon; L Wu; N L Zhu; M J Skotzko; V A Starnes; W F Anderson
Journal:  Hum Gene Ther       Date:  1997-12-10       Impact factor: 5.695

7.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells.

Authors:  H Hanenberg; X L Xiao; D Dilloo; K Hashino; I Kato; D A Williams
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

8.  Tumor induction of VEGF promoter activity in stromal cells.

Authors:  D Fukumura; R Xavier; T Sugiura; Y Chen; E C Park; N Lu; M Selig; G Nielsen; T Taksir; R K Jain; B Seed
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

9.  Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion.

Authors:  M D Pierschbacher; E Ruoslahti
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

10.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

View more
  10 in total

Review 1.  Bacteriophages and medical oncology: targeted gene therapy of cancer.

Authors:  Babak Bakhshinejad; Marzieh Karimi; Majid Sadeghizadeh
Journal:  Med Oncol       Date:  2014-07-11       Impact factor: 3.064

2.  Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.

Authors:  Roshank Ahani; Farzin Roohvand; Reza Ahangari Cohan; Mohammad Hossein Etemadzadeh; Nasir Mohajel; Mahdi Behdani; Zahra Shahosseini; Navid Madani; Kayhan Azadmanesh
Journal:  Mol Biotechnol       Date:  2016-11       Impact factor: 2.695

3.  Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues.

Authors:  Paola Di Matteo; Gian Luigi Arrigoni; Luca Alberici; Angelo Corti; Corrado Gallo-Stampino; Catia Traversari; Claudio Doglioni; Gian-Paolo Rizzardi
Journal:  J Histochem Cytochem       Date:  2011-01       Impact factor: 2.479

Review 4.  The neovasculature homing motif NGR: more than meets the eye.

Authors:  Angelo Corti; Flavio Curnis; Wadih Arap; Renata Pasqualini
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

5.  Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Authors:  Flavio Curnis; Angela Cattaneo; Renato Longhi; Angelina Sacchi; Anna Maria Gasparri; Fabio Pastorino; Paola Di Matteo; Catia Traversari; Angela Bachi; Mirco Ponzoni; Gian-Paolo Rizzardi; Angelo Corti
Journal:  J Biol Chem       Date:  2010-01-11       Impact factor: 5.157

6.  Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells.

Authors:  Lei Liu; Huixiang Li; Min Zhang; Xinquan Lv
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  NGR-peptide-drug conjugates with dual targeting properties.

Authors:  Kata Nóra Enyedi; Szilárd Tóth; Gergely Szakács; Gábor Mező
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

8.  Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain.

Authors:  Ryota Kirikoshi; Noriyoshi Manabe; Ohgi Takahashi
Journal:  Int J Mol Sci       Date:  2017-02-16       Impact factor: 5.923

9.  The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.

Authors:  Lauren R H Krumpe; Toshiyuki Mori
Journal:  Int J Pept Res Ther       Date:  2006-03-03       Impact factor: 1.931

10.  Recombinant IFN-α2a-NGR exhibits higher inhibitory function on tumor neovessels formation compared with IFN-α2a in vivo and in vitro.

Authors:  Weina Li; Qiang Hao; Liqing He; Jieru Meng; Meng Li; Xiaochang Xue; Cun Zhang; Hong Li; Wei Zhang; Yingqi Zhang
Journal:  Cytotechnology       Date:  2014-06-05       Impact factor: 2.058

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.